Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2022 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
May 08, 2020 09:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million ...
April 15, 2020 00:21 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
March 09, 2020 16:10 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
February 19, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
February 10, 2020 08:30 ET | Source: Rezolute, Inc.

Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism

REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
January 27, 2020 08:30 ET | Source: Rezolute, Inc.

Rezolute to Present at BIO CEO & Investor Conference 2020

REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...
January 02, 2019 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 20, 2018 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference

SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 13, 2018 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...

Next Page keyboard_arrow_right